<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445028</url>
  </required_header>
  <id_info>
    <org_study_id>WEI-DELIVER</org_study_id>
    <nct_id>NCT01445028</nct_id>
  </id_info>
  <brief_title>Isotretinoin for Proliferative Vitreoretinopathy</brief_title>
  <acronym>DELIVER</acronym>
  <official_title>Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an
      important cause of retinal re-detachment. The purpose of this study is to evaluate the effect
      of oral isotretinoin, which inhibits the growth of cells responsible for proliferative
      vitreoretinopathy (PVR), on recurrent retinal detachment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Small retrospective studies have shown isotretinoin to be effective in reducing the rate of
      recurrent retinal detachment in patients with or at high risk for developing PVR. This is a
      prospective study to evaluate a low dose of oral isotretinoin in this regard. There are two
      arms to the study: 1) eyes with recurrent retinal detachment due to existing PVR, and 2) eyes
      with primary detachment and features associated with a high risk of PVR formation. Eligible
      and willing patients will receive a 12-week course of isotretinoin, and will be followed for
      retinal attachment rate, and PVR and/or ERM (epiretinal membrane) formation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Retinal Attachment</measure>
    <time_frame>3 months</time_frame>
    <description>We will evaluate all patients for retinal attachment at 3 and 6-months following enrollment in the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Proliferative Vitreoretinopathy</condition>
  <arm_group>
    <arm_group_label>Primary, high-risk retinal detachment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recurrent RD associated with PVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Isotretinoin 20mg daily for 12 weeks</description>
    <arm_group_label>Primary, high-risk retinal detachment</arm_group_label>
    <arm_group_label>Recurrent RD associated with PVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 year-old men or 50-70 year-old, post-menopausal women.

          -  Healthy enough to participate in the study.

          -  Willing and able to consent to participation.

          -  Recurrent PVR-associated RD occurring at least 2 weeks after RD repair or

          -  Primary RD (retinal detachment) associated with one or more high-risk features

        Exclusion Criteria:

          -  History of hypersensitivity to isotretinoin.

          -  Current use of a corticosteroid (excluding topical).

          -  Any history of depression, anorexia, liver or pancreatic disease.

          -  More than one prior surgical RD repair.

          -  Patients with closed funnel retinal detachments.

          -  Patients with chronic retinal detachment, defined as longer than 12 weeks.

          -  Any use an oral retinoid within 6 months.

          -  Systemic chemotherapy within 6 months.

          -  Patients taking supplemental vitamin A.

          -  Corneal opacity sufficient to impair surgical view.

          -  Proliferative diabetic retinopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Kaiser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2017</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Richard S. Kaiser</investigator_full_name>
    <investigator_title>Associate Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Primary, High-risk Retinal Detachment</title>
          <description>Isotretinoin: Isotretinoin 20mg daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Recurrent RD Associated With PVR</title>
          <description>Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
Isotretinoin: Isotretinoin 20mg daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Primary, High-risk Retinal Detachment</title>
          <description>Isotretinoin: Isotretinoin 20mg daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Recurrent RD Associated With PVR</title>
          <description>Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
Isotretinoin: Isotretinoin 20mg daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="10.0"/>
                    <measurement group_id="B2" value="59.7" spread="11.8"/>
                    <measurement group_id="B3" value="57.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Retinal Attachment</title>
        <description>We will evaluate all patients for retinal attachment at 3 and 6-months following enrollment in the study.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primary, High-risk Retinal Detachment</title>
            <description>Isotretinoin: Isotretinoin 20mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Recurrent RD Associated With PVR</title>
            <description>Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
Isotretinoin: Isotretinoin 20mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Retinal Attachment</title>
          <description>We will evaluate all patients for retinal attachment at 3 and 6-months following enrollment in the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Primary, High-risk Retinal Detachment</title>
          <description>Isotretinoin: Isotretinoin 20mg daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Recurrent RD Associated With PVR</title>
          <description>Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
Isotretinoin: Isotretinoin 20mg daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Kaiser, MD</name_or_title>
      <organization>MidAtlantic Retina</organization>
      <phone>800-331-6634</phone>
      <email>rkaiser@midatlanticretina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

